Literature DB >> 27151105

β-cell specific T-lymphocyte response has a distinct inflammatory phenotype in children with Type 1 diabetes compared with adults.

S Arif1,2, V B Gibson1, V Nguyen1, P J Bingley3,2, J A Todd4,2, C Guy5,2, D B Dunger5,2, C M Dayan6, J Powrie7, A Lorenc8, M Peakman1,2.   

Abstract

AIM: To examine the hypothesis that the quality, magnitude and breadth of helper T-lymphocyte responses to β cells differ in Type 1 diabetes according to diagnosis in childhood or adulthood.
METHODS: We studied helper T-lymphocyte reactivity against β-cell autoantigens by measuring production of the pro-inflammatory cytokine interferon-γ and the anti-inflammatory cytokine interleukin-10, using enzyme-linked immunospot assays in 61 people with Type 1 diabetes (within 3 months of diagnosis, positive for HLA DRB1*0301 and/or *0401), of whom 33 were children/adolescents, and a further 91 were unaffected siblings.
RESULTS: Interferon-γ responses were significantly more frequent in children with Type 1 diabetes compared with adults (85 vs 61%; P = 0.04). Insulin and proinsulin peptides were preferentially targeted in children (P = 0.0001 and P = 0.04, respectively) and the breadth of the interferon-γ response was also greater, with 70% of children having an interferon-γ response to three or more peptides compared with 14% of adults (P < 0.0001). Islet β-cell antigen-specific interleukin-10 responses were similar in children and adults in terms of frequency, breadth and magnitude, with the exception of responses to glutamic acid decarboxylase 65, which were significantly less frequent in adults.
CONCLUSIONS: At diagnosis of Type 1 diabetes, pro-inflammatory autoreactivity is significantly more prevalent, focuses on a wider range of targets, and is more focused on insulin/proinsulin in children than adults. We interpret this as indicating a more aggressive immunological response in the younger age group that is especially characterized by loss of tolerance to proinsulin. These findings highlight the existence of age-related heterogeneity in Type 1 diabetes pathogenesis that could have relevance to the development of immune-based therapies.
© 2016 Diabetes UK.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27151105     DOI: 10.1111/dme.13153

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  17 in total

1.  Standardizing T-Cell Biomarkers in Type 1 Diabetes: Challenges and Recent Advances.

Authors:  Simi Ahmed; Karen Cerosaletti; Eddie James; S Alice Long; Stuart Mannering; Cate Speake; Maki Nakayama; Timothy Tree; Bart O Roep; Kevan C Herold; Todd M Brusko
Journal:  Diabetes       Date:  2019-07       Impact factor: 9.461

2.  Autoreactive T effector memory differentiation mirrors β cell function in type 1 diabetes.

Authors:  Lorraine Yeo; Alyssa Woodwyk; Sanjana Sood; Anna Lorenc; Martin Eichmann; Irma Pujol-Autonell; Rosella Melchiotti; Ania Skowera; Efthymios Fidanis; Garry M Dolton; Katie Tungatt; Andrew K Sewell; Susanne Heck; Alka Saxena; Craig A Beam; Mark Peakman
Journal:  J Clin Invest       Date:  2018-07-16       Impact factor: 14.808

Review 3.  The challenge of modulating β-cell autoimmunity in type 1 diabetes.

Authors:  Mark A Atkinson; Bart O Roep; Amanda Posgai; Daniel C S Wheeler; Mark Peakman
Journal:  Lancet Diabetes Endocrinol       Date:  2018-10-24       Impact factor: 32.069

4.  Single Islet Autoantibody at Diagnosis of Clinical Type 1 Diabetes is Associated With Older Age and Insulin Resistance.

Authors:  Maria J Redondo; Jay Sosenko; Ingrid Libman; Jennifer J F McVean; Mustafa Tosur; Mark A Atkinson; Dorothy Becker; Susan Geyer
Journal:  J Clin Endocrinol Metab       Date:  2020-05-01       Impact factor: 5.958

Review 5.  Type 1 Diabetes: A Chronic Anti-Self-Inflammatory Response.

Authors:  Matthew Clark; Charles J Kroger; Roland M Tisch
Journal:  Front Immunol       Date:  2017-12-22       Impact factor: 7.561

6.  In silico and ex vivo approaches indicate immune pressure on capsid and non-capsid regions of coxsackie B viruses in the human system.

Authors:  Rhiannon Kundu; Robin Knight; Meenakshi Dunga; Mark Peakman
Journal:  PLoS One       Date:  2018-06-20       Impact factor: 3.240

7.  Mass Cytometry Identifies Distinct Subsets of Regulatory T Cells and Natural Killer Cells Associated With High Risk for Type 1 Diabetes.

Authors:  Hugo Barcenilla; Linda Åkerman; Mikael Pihl; Johnny Ludvigsson; Rosaura Casas
Journal:  Front Immunol       Date:  2019-05-03       Impact factor: 7.561

8.  Characterization of Proinsulin T Cell Epitopes Restricted by Type 1 Diabetes-Associated HLA Class II Molecules.

Authors:  Emmi-Leena Ihantola; Henna Ilmonen; Anssi Kailaanmäki; Marja Rytkönen-Nissinen; Aurélien Azam; Bernard Maillère; Cecilia S Lindestam Arlehamn; Alessandro Sette; Keshav Motwani; Howard R Seay; Todd M Brusko; Mikael Knip; Riitta Veijola; Jorma Toppari; Jorma Ilonen; Tuure Kinnunen
Journal:  J Immunol       Date:  2020-03-30       Impact factor: 5.426

Review 9.  Interactions Between the Neuroendocrine System and T Lymphocytes in Diabetes.

Authors:  Luz Andreone; María Laura Gimeno; Marcelo J Perone
Journal:  Front Endocrinol (Lausanne)       Date:  2018-05-17       Impact factor: 5.555

Review 10.  Therapies to Suppress β Cell Autoimmunity in Type 1 Diabetes.

Authors:  Charles J Kroger; Matthew Clark; Qi Ke; Roland M Tisch
Journal:  Front Immunol       Date:  2018-08-16       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.